NasdaqCM - Delayed Quote USD

Helius Medical Technologies, Inc. (HSDT)

5.11 -0.05 (-0.97%)
At close: April 18 at 4:00 PM EDT
5.22 +0.11 (+2.15%)
After hours: April 18 at 5:03 PM EDT
Loading Chart for HSDT
DELL
  • Previous Close 5.16
  • Open 5.15
  • Bid 4.96 x 100
  • Ask 5.28 x 100
  • Day's Range 5.10 - 5.16
  • 52 Week Range 4.29 - 14.45
  • Volume 6,594
  • Avg. Volume 411,619
  • Market Cap (intraday) 4.534M
  • Beta (5Y Monthly) 1.55
  • PE Ratio (TTM) --
  • EPS (TTM) -14.56
  • Earnings Date May 9, 2024 - May 13, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 15.47

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

heliusmedical.com

22

Full Time Employees

December 31

Fiscal Year Ends

Recent News: HSDT

Performance Overview: HSDT

Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

HSDT
36.43%
S&P 500
5.06%

1-Year Return

HSDT
49.90%
S&P 500
20.71%

3-Year Return

HSDT
99.40%
S&P 500
19.73%

5-Year Return

HSDT
99.90%
S&P 500
72.77%

Compare To: HSDT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HSDT

Valuation Measures

As of 4/18/2024
  • Market Cap

    4.53M

  • Enterprise Value

    -590.92k

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.82

  • Price/Book (mrq)

    1.93

  • Enterprise Value/Revenue

    -0.92

  • Enterprise Value/EBITDA

    0.05

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -61.40%

  • Return on Equity (ttm)

    -168.55%

  • Revenue (ttm)

    644k

  • Net Income Avi to Common (ttm)

    -8.85M

  • Diluted EPS (ttm)

    -14.56

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.18M

  • Total Debt/Equity (mrq)

    2.43%

  • Levered Free Cash Flow (ttm)

    -6.11M

Research Analysis: HSDT

Analyst Price Targets

7.40
15.47 Average
5.11 Current
24.00 High
 

Fair Value

Overvalued
% Return
5.11 Current
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

People Also Watch